| abstract |
Referring to N-sulfonylated pyrazolo [3,4-b] pyridine-6-carboxamides compounds of formula (I), wherein R1 is G1A, C1-C6 haloalkyl or C1-C6 alkyl; G1A is 5-6 membered monocyclic phenyl heteroaryl, among others; R2 is hydrogen, C2-C4 alkenyl, C1-C6 alkyl, among others; R3 is G3A, -G3B-L1-G3C, among others; G3A, G3B and G3C are, independently C3-C11 cycloalkyl, phenyl, among others; L1 is a bond, C1-C6 alkylenyl, among others; R4 is hydrogen, C1-C3 alkyl, among others; R5 is C1-C6 alkyl, C2-C6 alkenyl, among others, and pharmaceutically acceptable salts thereof. These compounds are modulators of cystic fibrosis transmembrane conductance regulator protein (CFTR); being useful as agents in the treatment of CFTR-mediated and modulated diseases and conditions, including cystic fibrosis, Sjogren's syndrome, pancreatic insufficiency, chronic obstructive pulmonary disease, and chronic obstructive airway disease. |